Lexeo Therapeutics, Inc. Rings the Closing Bell

About This Event

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, R. Nolan Townsend, Lexeo Chief Executive Officer, rings the Closing Bell.

Nasdaq Originals Exclusive insights on the forces shaping the convergence of technology, business and sports. Explore